RG002
/ Rigerna Therap
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
November 10, 2024
A randomized, placebo-controlled, single/multiple dose escalation Phase 1 clinical study evaluating the safety/tolerability and pharmacokinetic/pharmacodynamic profile of RG002C0106 injection in healthy adults
(ChiCTR)
- P1 | N=50 | Not yet recruiting | Sponsor: Beijing Friendship Hospital ,Capital Medical University; Beijing Friendship Hospital ,Capital Medical University
New P1 trial • Renal Disease
July 10, 2024
A Phase 1 Study to Evaluate the Safety/Tolerability, PK/PD of RG002C0106 Injection in Healthy Adults
(clinicaltrials.gov)
- P1 | N=30 | Not yet recruiting | Sponsor: Rigerna Therapeutics, Beijing； Rigerna Therapeutics, Suzhou； Rigerna OA Therapeutics Pty Ltd
New P1 trial
1 to 2
Of
2
Go to page
1